Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours

[1]  F. Mottaghy,et al.  Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  L. Breimer,et al.  Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  G. Schmidt,et al.  The Role of 68Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors , 2012, The Journal of Nuclear Medicine.

[4]  P. Castaldi,et al.  Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis , 2012, Endocrine.

[5]  F. Mottaghy,et al.  Significant impact of transient deterioration of renal function on dosimetry in PRRT , 2012, Annals of Nuclear Medicine.

[6]  F. Mottaghy,et al.  Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Matthias Briel,et al.  Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Buchert,et al.  Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  I. Kayani,et al.  The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy , 2010, Journal of Nuclear Medicine.

[10]  E. Krenning,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with 111In-Pentetreotide , 2009, Neuroendocrinology.

[11]  R. Valkema,et al.  Peptide-receptor radionuclide therapy for endocrine tumors , 2009, Nature Reviews Endocrinology.

[12]  E. Krenning,et al.  Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Jensen,et al.  Gastroenteropancreatic neuroendocrine tumours. , 2008, The Lancet. Oncology.

[15]  A. Runz,et al.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  R. Bale,et al.  68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.

[17]  L. Strauss,et al.  Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  W. H. Knapp,et al.  68Ga-labelled DOTA-derivatised peptide ligands , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  J. Reubi,et al.  Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Uwe Haberkorn,et al.  Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[21]  P. Schöffski,et al.  Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data , 2001, European Journal of Nuclear Medicine.

[22]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[23]  E. Krenning,et al.  Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.